Search research articles
Contact Us
Filters
Showing results (21-30 of 49) with videos related to
Page
of 5
Sort By:
American Journal of Hematology
|
April 6, 2022
Prediction of survival with intensive chemotherapy in acute myeloid leukemia
Koji Sasaki, Farhad Ravandi, Tapan Kadia, et al.
Leukemia
|
September 5, 2025
Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome
Alexandre Bazinet, Guillermo Montalban-Bravo, Alex Bataller, et al.
Leukemia Research
|
April 19, 2025
Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome
Julie S Braish, Guillermo Montalban-Bravo, Farhad Ravandi, et al.
American Journal of Hematology
|
January 28, 2025
Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals
Jitesh D Kawedia, Caitlin R Rausch, Xiaoqian Liu, et al.
Blood Cancer Journal
|
January 18, 2019
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
Musa Yilmaz, Feng Wang, Sanam Loghavi, et al.
Hemasphere
|
October 24, 2025
A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia
Wei-Ying Jen, Jennifer Croden, Emmanuel Almanza-Huante, et al.
Cancer
|
July 17, 2019
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia
Koji Sasaki, Hagop M Kantarjian, Tapan Kadia, et al.
Cancer
|
March 13, 2019
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome
Kiran Naqvi, Koji Sasaki, Guillermo Montalban-Bravo, et al.
The Lancet. Haematology
|
March 28, 2024
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial
Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, et al.
Blood
|
October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2
Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 49) with videos related to
Sort By:
Page
of 5
American Journal of Hematology
|
April 6, 2022
Prediction of survival with intensive chemotherapy in acute myeloid leukemia
Koji Sasaki, Farhad Ravandi, Tapan Kadia, et al.
Leukemia
|
September 5, 2025
Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome
Alexandre Bazinet, Guillermo Montalban-Bravo, Alex Bataller, et al.
Leukemia Research
|
April 19, 2025
Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome
Julie S Braish, Guillermo Montalban-Bravo, Farhad Ravandi, et al.
American Journal of Hematology
|
January 28, 2025
Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals
Jitesh D Kawedia, Caitlin R Rausch, Xiaoqian Liu, et al.
Blood Cancer Journal
|
January 18, 2019
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
Musa Yilmaz, Feng Wang, Sanam Loghavi, et al.
Hemasphere
|
October 24, 2025
A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia
Wei-Ying Jen, Jennifer Croden, Emmanuel Almanza-Huante, et al.
Cancer
|
July 17, 2019
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia
Koji Sasaki, Hagop M Kantarjian, Tapan Kadia, et al.
Cancer
|
March 13, 2019
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome
Kiran Naqvi, Koji Sasaki, Guillermo Montalban-Bravo, et al.
The Lancet. Haematology
|
March 28, 2024
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial
Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, et al.
Blood
|
October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2
Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Page
of 5